A consensus statement on dual purpose pathogen surveillance systems: The always on approach PLOS Glob Public Health. 2024; 4(11):e0003762. . View in PubMed

An Inflection Point in Cancer Protein Biomarkers: What was and What's Next Mol Cell Proteomics. 2023 07; 22(7):100569. . View in PubMed

COVID-19 and other adult vaccines can drive global disease prevention Lancet. 2023 01 07; 401(10370):8-10. . View in PubMed

Successful adult vaccine drives must centre disability inclusion - Authors' reply Lancet. 2023 07 29; 402(10399):370. . View in PubMed

Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer Prostate Cancer Prostatic Dis. 2021 03; 24(1):61-68. . View in PubMed

Cancer Moonshot 20. Lancet Oncol. 2021 02; 22(2):164-165. . View in PubMed

High-throughput microscopy reveals the impact of multifactorial environmental perturbations on colorectal cancer cell growth Gigascience. 2021 04 19; 10(4). . View in PubMed

Paradoxical androgen receptor regulation by small molecule enantiomers Proc Natl Acad Sci U S A. 2021 03 23; 118(12). . View in PubMed

Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains Nat Commun. 2020 11 16; 11(1):5727. . View in PubMed

Deep learned tissue "fingerprints" classify breast cancers by ER/PR/Her2 status from H&E images Sci Rep. 2020 04 29; 10(1):7275. . View in PubMed

Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA) BMC Res Notes. 2019 May 15; 12(1):275. . View in PubMed

Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City Addict Behav. 2019 06; 93:14-19. . View in PubMed

Correlating nuclear morphometric patterns with estrogen receptor status in breast cancer pathologic specimens NPJ Breast Cancer. 2018; 4:32. . View in PubMed

Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC) Clin Genitourin Cancer. 2017 Jul 14. . View in PubMed

Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trialA registry-based randomized clinical trial. Am Heart J. 2017 Jul; 189:94-102. . View in PubMed

Future cancer research priorities in the USA: a Lancet Oncology Commission Lancet Oncol. 2017 11; 18(11):e653-e706. . View in PubMed

JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines Mol Cancer Ther. 2017 08; 16(8):1645-1657. . View in PubMed

Quantifying differences in cell line population dynamics using CellPD BMC Syst Biol. 2016 Sep 21; 10(1):92. . View in PubMed

Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS) Sci Rep. 2016 Mar 03; 6:22435. . View in PubMed

A Plasma-Based Protein Marker Panel for Colorectal Cancer Detection Identified by Multiplex Targeted Mass SpectrometryClin Colorectal Cancer. 2016 06; 15(2):186-194. e13. . View in PubMed

THE DOCTOR WILL SEE YOU (AND YOUR DATA) NOW Fortune. 2016 Jan 01; 173(1):90-3. . View in PubMed

Single cell dynamic phenotyping Sci Rep. 2016 10 06; 6:34785. . View in PubMed

A high-content image-based method for quantitatively studying context-dependent cell population dynamics Sci Rep. 2016 07 25; 6:29752. . View in PubMed

The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older PLoS One. 2016; 11(11):e0166103. . View in PubMed

Stochasticity and determinism in cancer creation and progression Converg Sci Phys Oncol. 2015 Dec; 1(2). . View in PubMed

Aligning incentives to fulfil the promise of personalised medicine Lancet. 2015 May 23; 385(9982):2118-9. . View in PubMed

Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer Invest New Drugs. 2015 Apr; 33(2):397-408. . View in PubMed

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5 J Clin Oncol. 2015 Mar 01; 33(7):723-31. . View in PubMed

Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors Psychooncology. 2015 Feb; 24(2):228-35. . View in PubMed

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells Cancer Inform. 2015; 14(Suppl 4):19-31. . View in PubMed

Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer Clin Cancer Res. 2014 Mar 01; 20(5):1335-44. . View in PubMed

The Value of Diagnostic Testing in Personalized Medicine Forum Health Econ Policy. 2013 Sep 01; 16(2):S87-S99. . View in PubMed

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors Invest New Drugs. 2013 Apr; 31(2):409-16. . View in PubMed

Body image predicts quality of life in men with prostate cancer Psychooncology. 2013 Apr; 22(4):756-61. . View in PubMed

Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype Prostate. 2013 Feb 15; 73(3):306-15. . View in PubMed

A physical sciences network characterization of non-tumorigenic and metastatic cells Sci Rep. 2013; 3:1449. . View in PubMed

Perspective: Meeting of minds Nature. 2012 Nov 22; 491(7425):S61. . View in PubMed

Reframe the health debate Fortune. 2012 Oct 29; 166(7):22. . View in PubMed

A cross-platform toolkit for mass spectrometry and proteomics Nat Biotechnol. 2012 Oct; 30(10):918-20. . View in PubMed

Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition Mol Cancer Ther. 2012 May; 11(5):1071-81. . View in PubMed

Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs. 2012 Apr; 30(2):749-57. . View in PubMed

Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. . View in PubMed

Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer Mol Pharm. 2011 Dec 05; 8(6):2069-79. . View in PubMed

Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors Genome Res. 2011 Jan; 21(1):47-55. . View in PubMed

Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma PLoS One. 2011; 6(7):e23090. . View in PubMed

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer Clin Chem. 2010 Sep; 56(9):1492-5. . View in PubMed

Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling Prostate. 2010 Aug; 70(11):1201-10. . View in PubMed

Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs Mol Cancer Res. 2010 Jun; 8(6):809-20. . View in PubMed

HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation Cancer Res. 2010 Mar 01; 70(5):1989-99. . View in PubMed

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes Mol Cancer Ther. 2009 Oct; 8(10):2882-93. . View in PubMed

Multiparameter computational modeling of tumor invasion Cancer Res. 2009 May 15; 69(10):4493-501. . View in PubMed

Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping Psychooncology. 2009 May; 18(5):508-14. . View in PubMed

ProteoWizard: open source software for rapid proteomics tools development Bioinformatics. 2008 Nov 01; 24(21):2534-6. . View in PubMed

Precursor-ion mass re-estimation improves peptide identification on hybrid instruments J Proteome Res. 2008 Sep; 7(9):4031-9. . View in PubMed

Personalized genetics: a responsible approach Am J Hum Genet. 2008 Jul; 83(1):130; author reply 131. . View in PubMed

The current state of preclinical prostate cancer animal models Prostate. 2008 May 01; 68(6):629-39. . View in PubMed

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer BMC Cancer. 2007 Jul 27; 7:142. . View in PubMed

Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer Clin Cancer Res. 2007 Apr 01; 13(7):1979-86. . View in PubMed

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy J Clin Oncol. 2007 Feb 20; 25(6):675-81. . View in PubMed

Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer Clin Cancer Res. 2007 Feb 15; 13(4):1208-15. . View in PubMed

Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery Clin Adv Hematol Oncol. 2006 Jul; 4(7):541-9. . View in PubMed

Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial BJU Int. 2006 Apr; 97(4):691-7. . View in PubMed

Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies Br J Cancer. 2006 Jan 16; 94(1):85-92. . View in PubMed

2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth Cancer. 2005 Dec 15; 104(12):2701-8. . View in PubMed

A perspective on protein profiling of blood BJU Int. 2005 Sep; 96(4):477-82. . View in PubMed

Epithelial membrane protein-1 is a biomarker of gefitinib resistance Proc Natl Acad Sci U S A. 2005 Aug 16; 102(33):11858-63. . View in PubMed

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer J Clin Oncol. 2005 Apr 10; 23(11):2534-43. . View in PubMed

PPARgamma signaling: one size fits all? Cell Cycle. 2004 Nov; 3(11):1352-4.. View in PubMed

CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts Prostate. 2004 Nov 01; 61(3):228-35. . View in PubMed

Ductal adenocarcinoma of the prostate Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. . View in PubMed

Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma Cancer Cell. 2004 Jun; 5(6):565-74. . View in PubMed

Targeting the HER-kinase axis in cancer Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. . View in PubMed

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol. 2004 Feb 01; 22(3):537-56. . View in PubMed

Update on HER-kinase-directed therapy in prostate cancer Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-664. . View in PubMed

Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse Cancer Res. 2003 Jul 15; 63(14):4196-203. . View in PubMed

Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition J Natl Cancer Inst. 2002 Nov 06; 94(21):1641-7. . View in PubMed

Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer Clin Cancer Res. 2002 Oct; 8(10):3226-31. . View in PubMed

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth Cancer Cell. 2002 Aug; 2(2):127-37. . View in PubMed

TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells Oncogene. 2002 Jul 18; 21(31):4739-46. . View in PubMed

Vaccination with CD20 peptides induces a biologically active, specific immune response in mice Blood. 2002 May 15; 99(10):3748-55. . View in PubMed

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts Clin Cancer Res. 2002 May; 8(5):986-93. . View in PubMed

Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke Proc Natl Acad Sci U S A. 2001 Sep 25; 98(20):11720-4. . View in PubMed

HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer Clin Cancer Res. 2001 Sep; 7(9):2643-7. . View in PubMed

Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase Clin Cancer Res. 2001 Apr; 7(4):962-70. . View in PubMed

A potential role for activated HER-2 in prostate cancer Semin Oncol. 2000 Dec; 27(6 Suppl 11):76-83; discussion 92-100. . View in PubMed

HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer Semin Oncol. 2000 Dec; 27(6 Suppl 11):53-63; discussion 92-100. . View in PubMed

Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1 Cancer Res. 2000 Nov 01; 60(21):6134-41. . View in PubMed

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo Cancer Res. 2000 Sep 15; 60(18):5165-70. . View in PubMed

Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors Cancer Res. 2000 May 01; 60(9):2317-22. . View in PubMed

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma J Clin Oncol. 1999 Dec; 17(12):3776-85. . View in PubMed

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence J Natl Cancer Inst. 1999 Nov 03; 91(21):1869-76. . View in PubMed

Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models Cancer Res. 1999 Oct 01; 59(19):4761-4. . View in PubMed

Stromal cell oxidation: a mechanism by which tumors obtain vitamin C Cancer Res. 1999 Sep 15; 59(18):4555-8. . View in PubMed

Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal Cancer Res. 1998 Jul 15; 58(14):3009-14. . View in PubMed

Workgroup 2: human xenograft models of prostate cancer Prostate. 1998 Jun 15; 36(1):56-8. . View in PubMed

Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters J Clin Invest. 1997 Dec 01; 100(11):2842-8. . View in PubMed

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia J Immunother (1991). 2001 May; 24(3):272-279. . View in PubMed